And in the first half of 2019, there are 12 drug inspection notices published on the website of Center for Food and Drug Inspection, NMPA, among which 3 companies are given the penalty of sales suspension in China. However, the imported drug manufacturers still experienced a much lower inspection frequency comparing to local companies. Although this new regulation can be considered as a signal that China authority wants to treat foreign companies and domestic companies equally, before that they still have the staff shortage problem to solve.